Keystone Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2006



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Pain Mechanisms and the Development of Analgesics (E5)


Organizer(s) Tony L. Yaksh, Mitchell B. Max, James C. Eisenach, Patrick W. Mantyh and Frank Porreca
June 11—16, 2006
Keystone Resort • Keystone, Colorado USA
Abstract Deadline: Feb 9, 2006
Late Abstract Deadline: Apr 11, 2006
Scholarship Deadline: Feb 9, 2006
Early Registration Deadline: Apr 11, 2006

Supported by The Director's Fund

Summary of Meeting:
Pain and its control are appreciated to be a major medical problem. Over the past 20 years there have been major advances in our understanding of the mechanisms by which information leading to a pain state is processed. In spite of these substantial insights into the complex pharmacology, the translation of mechanistic data into clinically relevant drugs has been tedious. Several problems are recognized. First, an important problem relates to the interpretation of the preclinical behavioral models with respect to predicting human efficacy and whether specific models adequately predict outcomes in different pain states. Second, it is believed that the human experimental model would provide important insights into efficacy early in the drug development process, but validation of this model has been difficult. The meeting will first review the current thinking regarding the mechanisms whereby information generated by acute stimulation, tissue injury and nerve injury are encoded in a manner so as to present a pain state. Secondly, the preclinical surrogate models which present the behavioral expression of the noxious event will be reviewed and cross model consistency and reliability will be reviewed. Thirdly, we will review the experimental human models that provide a correlate in human volunteers of the preclinically defined pain mechanisms and consider their ability to predict drug activity in pathological states. Finally, presenters will review the implementation of human trials which define the analgesic efficacy of drug therapies. An important aspect of these 4 components is the frequent implementation of case-based parallels that reflect successes in prediction (e.g. COX2 inhibitors, GABApentin, ziconotide) and failures (NK1 antagonist).

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, JUNE 11

15:00—19:30
Registration

Gallery
18:30—19:30
Refreshments

Gallery & Lakeside Suite
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Arapahoe
Mitchell B. Max, University of Pittsburgh, Center for Pain Research,
Dissecting Chronic Pain Syndromes as Complex Genetic Disorders


MONDAY, JUNE 12

07:00—08:00
Breakfast

Bighorn/Champeaux
08:00—11:00
Pharmacology of Pain Encoding I... Rational Targets of Analgesic Development
Meeting has ended...abstracts no longer viewable online.

Arapahoe
* James C. Eisenach, Wake Forest University School of Medicine, USA

Jon Levine, University of California, San Francisco, USA
Pain Mechanisms and the Development of Analgesics: Target Practice

Clifford J. Woolf, Children's Hospital, USA
Facilitatory Cascades in Post Injury States

Stephen B. McMahon, King's College London, UK
CCL2 as a Mediator of Neuropathic Pain

09:20—09:40
Coffee Break

Gallery & Lakeside Suite
11:00—13:00
Poster Setup

Divide/Ten Mile
13:00—22:00
Poster Viewing

Divide/Ten Mile
14:30—16:30
Workshop 1
1) Cascades upon cascades.. does any one of them really matter? 2) Is neuropathic pain after peripheral nerve injury a question of persistent afferent traffic? 3) The sprouting axon, afferents to sympathetics in nerve injury induced pain states. 4) What makes a terminal discharge after local tissue inflammation? 5) Where is the convergence between tissue and nerve injury pain mechanisms? 6) The hottest target: left vs right brain choices?

Arapahoe
* James C. Eisenach, Wake Forest University School of Medicine, USA

Short Talk(s) Chosen from Abstracts

16:30—17:00
Coffee Available

Gallery & Lakeside Suite
17:00—19:00
Preclinical Behavioral Models: Models of Mechanisms and Predictive Surrogates for the Human Experience? I
Meeting has ended...abstracts no longer viewable online.

Arapahoe
* James C. Eisenach, Wake Forest University School of Medicine, USA

Timothy Brennan, University of Iowa, USA
Acute-Postoperative Pain

Frank Porreca, University of Arizona, USA
Peripheral and Central Sensitization in Chronic Pain of Osteoarthritis and Rheumatoid Arthritis

Theo F. Meert, Johnson & Johnson Pharmaceutical Research & Development, LLC, Belgium
Nerve Injury Models

19:00—20:00
Social Hour with Lite Bites

Divide/Ten Mile
19:30—22:00
Poster Session 1

Divide/Ten Mile

TUESDAY, JUNE 13

07:00—08:00
Breakfast

Bighorn/Champeaux
08:00—11:00
Preclinical Behavioral Models: Models of Mechanisms and Predictive Surrogates for the Human Experience? II
Meeting has ended...abstracts no longer viewable online.

Arapahoe
* Tony L. Yaksh, University of California, San Diego, USA

Patrick W. Mantyh, University of Arizona, USA
Mechanisms that Drive Cancer Pain

Jerry F. Gebhart, University of Pittsburgh, USA
Preclinical Models: Visceral Pain States

Nigel A. Calcutt, University of California, San Diego, USA
Painful Diabetic Neuropathy: Peripheral vs Central Mechanisms and Therapies

Robert P. Yezierski, University of Florida, USA
The Injured Spinal Cord: At-Level Versus Below-Level Pain

09:20—09:40
Coffee Break

Gallery & Lakeside Suite
11:00—13:00
Poster Setup

Divide/Ten Mile
13:00—22:00
Poster Viewing

Divide/Ten Mile
14:30—16:30
Workshop 2
1) Pharmacological Convergence between animal models…whither internal consistency. or are differences meaningful? 2) Model Potency; how good does the response have to be to be meaningful in humans, or does the preclinical profile mean anything in predicting human target? 3) When does the pain surrogate fail in predicting human analgesic efficacy? 4) Do side effects count in predicting efficacy?

Arapahoe
* Tony L. Yaksh, University of California, San Diego, USA

Victor J. Hruby, University of Arizona, USA
Addressing the Mechanism of Prolonged and Neuropathic Pain with Novel Ligands that are Agonists at Opioid Receptors and Antagonists at NK-1 or CCK Receoptors

Short Talk(s) Chosen from Abstracts

16:30—17:00
Coffee Available

Gallery & Lakeside Suite
17:00—19:00
Human Experimental Pain Model
Meeting has ended...abstracts no longer viewable online.

Arapahoe
* Tony L. Yaksh, University of California, San Diego, USA

Lars Arendt-Nielsen, Aalborg University, Denmark
Experimental Models of Pain in Human

Irene Tracey, University of Oxford, UK
Developing Human FMRI and EEG as Surrogate Markers of Pain Processing and Pharmacological Analgesia

19:00—20:00
Social Hour with Lite Bites

Divide/Ten Mile
19:30—22:00
Poster Session 2

Divide/Ten Mile

WEDNESDAY, JUNE 14

07:00—08:00
Breakfast

Bighorn/Champeaux
08:00—11:00
Organization of Clinical Analgesic Studies
Meeting has ended...abstracts no longer viewable online.

Arapahoe
* Mitchell B. Max, University of Pittsburgh, Center for Pain Research,

Paul J. Desjardins, Pfizer Consumer Healthcare, USA
Acute Postoperative Pain Models and Their Predictive Validity

Jennifer A. Haythornthwaite, Johns Hopkins University, USA
Psychological Variables in Trial Design and Efficacy Assessment

Dan Clauw, University of Michigan Medical School, USA
Studies of Complex Pain Syndromes: Fibromyalgia and Related Regional Pain Syndromes

John T. Farrar, University of Pennsylvania School of Medicine, USA
The Design of Clinical Trials and Analgesic Drug Research

09:20—09:40
Coffee Break

Gallery & Lakeside Suite
14:30—16:30
Workshop 3
1) Is there a value of experimental pain drug assessment in drug development, in achieving drug approval? 2) What end points matter?

Arapahoe
* Mitchell B. Max, University of Pittsburgh, Center for Pain Research,

* Lars Arendt-Nielsen, Aalborg University, Denmark

16:30—17:00
Coffee Available

Gallery & Lakeside Suite
17:00—19:00
Panel Discussion: Approval of Analgesic Drugs

Arapahoe
Bob A. Rappaport, U.S. Food and Drug Administration, USA
A Common Sense Approach to Analgesic Drug Development and Approval

Mitchell B. Max, University of Pittsburgh, Center for Pain Research,

Dan Clauw, University of Michigan Medical School, USA

John T. Farrar, University of Pennsylvania School of Medicine, USA

Paul J. Desjardins, Pfizer Consumer Healthcare, USA

Lars Arendt-Nielsen, Aalborg University, Denmark

19:00—20:00
Social Hour with Lite Bites

Divide/Ten Mile

THURSDAY, JUNE 15

07:00—08:00
Breakfast

Bighorn/Champeaux
08:00—11:00
Case Studies in Analgesic Development I
Meeting has ended...abstracts no longer viewable online.

Arapahoe
Charles P. Taylor, Pfizer Global Research & Development, USA
Case Review of Gabapentin and Pregabalin

Ray G. Hill, Merck & Co., Inc., UK
The Development of Substance P (NK1 Receptor) Antagonists as Putative Analgesics

Stuart Apfel, Dov Pharmaceutical Inc., USA
Bicifadine, A Novel Reuptake Inhibitor, In the Treatment of Chronic and Acute Pain

09:20—09:40
Coffee Break

Gallery & Lakeside Suite
02:30—04:30
Workshop 4
1) What constitutes preclinical evidence for efficacy 2) Go/ No-go decision points

Arapahoe
16:30—17:00
Coffee Available

Gallery & Lakeside Suite
17:00—19:00
Case Studies in Analgesic Drug development II
Meeting has ended...abstracts no longer viewable online.

Arapahoe
Jonathan Moss, University Of Chicago, USA
Development of Methylnaltrexone: Pain Relief Without Side Effects

Smriti Iyengar, Eli Lilly and Company, USA
Case Review of Duloxetine

19:00—20:00
Social Hour with Lite Bites

Divide/Gallery/Lakeside Suite
20:00—23:00
Entertainment

Divide

FRIDAY, JUNE 16

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13 DA021484-01




We gratefully acknowledge additional support for this conference from:

AstraZeneca R&D Montréal Educational donation provided by Amgen
Novartis Institutes for BioMedical Research
 

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Merck & Co., Inc.


Pfizer Inc.


Progenics Pharmaceuticals, Inc.


Wyeth Consumer Healthcare


Wyeth Pharmaceuticals


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676